Immunotherapy for Non-melanoma Skin Cancer.
Sophia Z ShalhoutKevin S EmerickHoward L KaufmanDavid M MillerPublished in: Current oncology reports (2021)
Several agents were recently U.S. Food and Drug Administration (FDA)-approved for the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma, Merkel cell carcinoma, and basal cell carcinoma. However, recent approvals in tissue-agnostic indications may also benefit other NMSCs including cutaneous adnexal solid tumors with high tumor mutation burdens or microsatellite instability. Furthermore, while FDA-approved indications will likely continue to expand, continued studies are needed to support the role of immunotherapy in the neoadjuvant, adjuvant, and refractory settings. Immunotherapy is emerging as the standard of care for several advanced NMSCs not amenable to surgery and radiation. Ongoing evaluation of the clinical trial landscape is needed to optimize enrollment and ensure continued innovation.
Keyphrases
- drug administration
- locally advanced
- squamous cell carcinoma
- skin cancer
- basal cell carcinoma
- rectal cancer
- clinical trial
- neoadjuvant chemotherapy
- phase ii study
- minimally invasive
- healthcare
- small cell lung cancer
- early stage
- lymph node metastasis
- palliative care
- coronary artery bypass
- randomized controlled trial
- lymph node
- affordable care act
- double blind
- smoking cessation
- radiation induced
- open label
- combination therapy
- genetic diversity
- chronic pain
- climate change